149 related articles for article (PubMed ID: 28688873)
21. Evidence for treating peripheral arterial diseases with biodegradable scaffolds.
Chu TM; Chan YC; Cheng SW
J Cardiovasc Surg (Torino); 2017 Feb; 58(1):87-94. PubMed ID: 26334047
[TBL] [Abstract][Full Text] [Related]
22. The Impact of Extracorporeal Shock Wave Therapy on Microcirculation in Diabetic Feet: A Pilot Study.
Yang JP; Lee YN; Son JW; Han SK
Adv Skin Wound Care; 2019 Dec; 32(12):563-567. PubMed ID: 31764146
[TBL] [Abstract][Full Text] [Related]
23. Vasoactive enzymes and blood flow responses to passive and active exercise in peripheral arterial disease.
Walker MA; Hoier B; Walker PJ; Schulze K; Bangsbo J; Hellsten Y; Askew CD
Atherosclerosis; 2016 Mar; 246():98-105. PubMed ID: 26771386
[TBL] [Abstract][Full Text] [Related]
24. A meta-analysis to compare Dacron versus polytetrafluroethylene grafts for above-knee femoropopliteal artery bypass.
Rychlik IJ; Davey P; Murphy J; O'Donnell ME
J Vasc Surg; 2014 Aug; 60(2):506-15. PubMed ID: 24973288
[TBL] [Abstract][Full Text] [Related]
25. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
[TBL] [Abstract][Full Text] [Related]
26. Relationship between endothelial function of micro- and macrocirculation in patients with peripheral arterial disease.
Poredoš P; Bešič H; Jeraj L
Vasa; 2017 Jan; 46(1):17-22. PubMed ID: 27871219
[TBL] [Abstract][Full Text] [Related]
27. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal.
Lawall H; Bramlage P; Amann B
Thromb Haemost; 2010 Apr; 103(4):696-709. PubMed ID: 20174766
[TBL] [Abstract][Full Text] [Related]
28. Placenta-derived PLX-PAD mesenchymal-like stromal cells are efficacious in rescuing blood flow in hind limb ischemia mouse model by a dose- and site-dependent mechanism of action.
Zahavi-Goldstein E; Blumenfeld M; Fuchs-Telem D; Pinzur L; Rubin S; Aberman Z; Sher N; Ofir R
Cytotherapy; 2017 Dec; 19(12):1438-1446. PubMed ID: 29122516
[TBL] [Abstract][Full Text] [Related]
29. Extended Extracorporeal Shockwave Therapy for Chronic Diabetic Foot Ulcers: A Case Series.
Chou WY; Wang CJ; Cheng JH; Chen JH; Chen CC; Kuo YR
Wounds; 2019 May; 31(5):132-136. PubMed ID: 30990778
[TBL] [Abstract][Full Text] [Related]
30. Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials.
Hammer A; Steiner S
Vasa; 2013 Sep; 42(5):331-9. PubMed ID: 23989068
[TBL] [Abstract][Full Text] [Related]
31. Minimising failure in critical lower limb ischaemia intervention: Adjuvant capillary bed recruitment is the missed opportunity.
Sultan S; Kavanagh EP; Hynes N
Vascular; 2018 Aug; 26(4):449-454. PubMed ID: 29419359
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of muscle morphology and function in intermittent claudication.
Harwood AE; King S; Totty J; Smith GE; Vanicek N; Chetter IC
J Vasc Surg; 2017 Oct; 66(4):1241-1257. PubMed ID: 28822657
[TBL] [Abstract][Full Text] [Related]
33. [The opportunities for genic therapy of chronic obliterating diseases of lower limbs arteries].
Cherviakov IuA; Staroverov IN; Nersesian EG; Vlasenko ON; Isaev AA; Deev RV
Khirurgiia (Mosk); 2014; (4):40-5. PubMed ID: 24816386
[No Abstract] [Full Text] [Related]
34. (2-Hydroxypropyl)-β-Cyclodextrin Is a New Angiogenic Molecule for Therapeutic Angiogenesis.
Qi X; Yuan Y; Xu K; Zhong H; Zhang Z; Zhai H; Guan G; Yu G
PLoS One; 2015; 10(5):e0125323. PubMed ID: 25944736
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Effects of Extracorporeal Shockwave Therapy in Patients With Peripheral Arterial Disease: A Meta-Analysis of Randomized Control Trials.
Munir Z; Akash M; Jaiprada F; Abu Tarboush B; Ijaz O; Bseiso A; Palleti SK; Amin A
Cureus; 2023 Feb; 15(2):e34729. PubMed ID: 36909116
[TBL] [Abstract][Full Text] [Related]
36. The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease.
Kashyap VS; Lakin RO; Campos P; Allemang M; Kim A; Sarac TP; Hausladen A; Stamler JS
J Vasc Surg; 2017 Jul; 66(1):187-194. PubMed ID: 28366306
[TBL] [Abstract][Full Text] [Related]
37. PAD in women: the ischemic continuum.
Pollak AW
Curr Atheroscler Rep; 2015 Jun; 17(6):513. PubMed ID: 25939674
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic arteriogenesis in peripheral arterial disease: combining intervention and passive training.
Bondke Persson A; Buschmann EE; Lindhorst R; Troidl K; Langhoff R; Schulte KL; Buschmann I
Vasa; 2011 May; 40(3):177-87. PubMed ID: 21638246
[TBL] [Abstract][Full Text] [Related]
39. Selected angiogenic factors in plasma of patients with lower limb symptomatic peripheral arterial disease: preliminary report.
Wieczór R; Gadomska G; Góralczyk B; Stankowska K; Budzyński J; Fabisiak J; Suppan K; Pulkowski G; Rość D
Int Angiol; 2015 Dec; 34(6):545-51. PubMed ID: 25394959
[TBL] [Abstract][Full Text] [Related]
40. Surgical and endovascular venous arterialization: ready to take the "desert" by storm?
Schreve MA; Ünlü Ç; Kum S; Tan YK
J Cardiovasc Surg (Torino); 2017 Jun; 58(3):402-408. PubMed ID: 28155264
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
